查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970821

静脉血栓栓塞症预防市场－全球产业规模、份额、趋势、机会、预测：按类型、最终用途、地区和竞争格局划分，2021-2031年

Venous Thromboembolism Prophylaxis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球静脉血栓栓塞症预防市场预计将从 2025 年的 68.9 亿美元成长到 2031 年的 95.7 亿美元，复合年增长率为 5.63%。

此治疗领域涉及抗凝血剂的使用和机械加压装置的应用，旨在预防深层静脉栓塞症和肺动脉栓塞。市场成长趋势的主要驱动因素是全球人口老化以及需要严格术后预防保健的大型心臟和整形外科手术住院率的不断上升。此外，人们日益认识到医院获得性血栓症形成是一种可预防的死亡原因，这也持续推动了医疗机构对有效干预通讯协定的需求。

市场概览
预测期 2027-2031
市场规模：2025年 68.9亿美元
市场规模：2031年 95.7亿美元
复合年增长率：2026-2031年 5.63%
成长最快的细分市场 门诊部
最大的市场 北美洲

儘管有这些成长要素，强效药物相关的出血风险仍然是一个主要障碍，可能导致临床医生无法严格遵守预防指引。这种谨慎的做法限制了市场渗透率，儘管需要关注的凝血障碍盛行率很高。根据国际血栓与止血学会的数据，到2024年，血栓症相关疾病将占全球死亡人数的四分之一，凸显了在扩大预防措施覆盖范围时，平衡治疗效果与患者安全至关重要。

市场驱动因素

大型外科手术和整形外科手术数量的增加是推动市场成长的关键因素，因此需要严格的术后预防策略以确保病人安全。随着医疗系统逐步清除与疫情相关的未治疗病例，全膝关节和髋置换术等高风险手术的频率也在增加，这直接推动了药物预防和机械置换术的使用。随着手术量的增加，储备和使用预防性解决方案以降低与手术伤口和长期煞车相关的深层静脉栓塞症形成风险，已成为医院的必要之举。根据史赛克公司于2024年1月发布的2023年第四季财报，该公司净销售额成长11.5%，达到58亿美元。这一业绩主要归功于需要同时进行预防性护理的手术数量的持续增长。

同时，新型口服抗凝血剂（NOACs）的快速普及正在改变标准治疗方案，与传统维生素K拮抗剂相比，NOACs具有更优的安全性和更便捷的给药方式。临床医生越来越倾向于选择这些先进的疗法，因为其可预测的药物动力学特性能够提高患者的依从性，并减少持续监测的需求。根据百时美施贵宝公司2023财年（2024年2月）的年度报告，其旗舰口服抗凝血剂艾乐妥（Eliquis）的全球销售额达到122亿美元，显示全球正在发生向这些现代药物的大规模转变。持续的疾病负担进一步凸显了这一转变。根据美国血栓症）预测，到2024年，美国每年将有约90万人受到血栓症的影响，这更加凸显了在整个治疗过程中采取可靠的预防干预措施的迫切性。

市场挑战

全球静脉血栓栓塞症预防市场面临的主要障碍之一是强效抗凝血​​治疗相关的严重出血风险。临床医生经常面临两难：既要权衡血栓预防的益处，又要考虑可能危及生命的出血併发症，尤其是在老年人和术后康復患者等脆弱人群中。这种临床谨慎往往导致处方不足、剂量减重或过早停止必要的预防性治疗。虽然这些顾虑在临床上是合理的，但它们限制了抗凝血剂的整体使用，并延缓了预防通讯协定的推广，阻碍了市场的整体成长。

这种限制在高风险患者族群中尤为严重，而这类人群恰恰占目标市场的很大一部分。根据美国血液学会统计，2023年，住院病患和长期照护机构的居民约占全球所有静脉血栓栓塞症病例的20%至25%。由于这些特定族群通常合併多种疾病，增加了出血风险，因此出于安全考虑，严格执行预防措施往往受到阻碍，从而有效地限制了市场渗透，而这部分人群原本会对预防性干预措施产生巨大的需求。

市场趋势

携带式穿戴式机械预防设备的兴起，正在改变復健方式，使压迫疗法摆脱对固定医院环境的依赖。与将患者限制在床边的传统气动系统不同，这些电池驱动装置能够让患者儘早活动，这对于减少静脉淤血和提高出院后患者的依从性至关重要。这种转变顺应了人们对居家復健解决方案日益增长的需求，这些方案既能保持临床疗效，又不限制患者的活动能力。主要产业参与者的财务表现凸显了这些技术的商业性可行性。根据Enobis公司于2024年2月发布的“2023财年第四季度及全年业绩报告”，该公司预防与康復部门的全年净销售额增长了5%，反映了市场对这些移动治疗解决方案的持续需求。

同时，利用人工智慧驱动的风险评估进行个人化预防通讯协定的采用正日益普及，成为精准医疗工具，取代了传统的通用预防策略。先进的演算法与电子健康记录系统集成，持续监测患者数据，并自动识别可能被人工评分系统（例如帕多瓦评分和卡普利尼评分）遗漏的高风险患者。这种自动化确保了对肺动脉栓塞等疾病的及时干预，并改善了分散的医院部门之间的护理协调。这些智慧型系统的快速普及也体现在专业人工智慧提供者日益增长的影响力上。根据 Viz.ai 于 2024 年 1 月发布的新闻稿《Viz.ai 在美国的医院应用程式已超过 1500 家》，其人工智慧疾病检测平台的用户群在 2023 年增长了约 30%，达到 45,000 名医疗保健提供者。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：静脉血栓栓塞症预防的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（下肢、上肢）
    • 依用途（医院/诊所、门诊部、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美静脉血栓栓塞症预防市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲静脉血栓栓塞症预防市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区静脉血栓栓塞症预防市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章 中东和非洲静脉静脉血栓栓塞症预防市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲静脉血栓栓塞症预防市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球静脉血栓栓塞症预防市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Arjo
  • Encompass Group
  • Argon Medical Devices
  • MEGO AFEK
  • Zenith Technical Innovations
  • Cook Medical
  • Bio Compression Systems
  • ThermoTek USA
  • Boston Scientific Corporation
  • Cardinal Health

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19024

The Global Venous Thromboembolism Prophylaxis Market is projected to expand from USD 6.89 Billion in 2025 to USD 9.57 Billion by 2031, progressing at a CAGR of 5.63%. This therapeutic sector encompasses the administration of anticoagulants alongside mechanical compression devices, all aimed at averting deep vein thrombosis and pulmonary embolism. The market's upward trajectory is primarily fueled by an aging global population and increasing hospitalization rates for major cardiac and orthopedic surgeries that mandate rigorous postsurgical preventative care. Additionally, the heightened acknowledgment of hospital-acquired clots as a preventable cause of mortality continues to uphold the demand for effective intervention protocols within healthcare facilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.89 Billion
Market Size 2031USD 9.57 Billion
CAGR 2026-20315.63%
Fastest Growing SegmentAmbulatory Care Centers
Largest MarketNorth America

Despite these growth drivers, the market faces significant hurdles due to the bleeding risks linked to potent pharmacological agents, which can discourage clinicians from strictly adhering to prophylactic guidelines. This caution restricts market penetration, even with the high prevalence of clotting disorders requiring attention. According to the International Society on Thrombosis and Haemostasis, in 2024, thrombosis-related conditions were responsible for one in four deaths globally, highlighting the critical need to balance therapeutic efficacy with patient safety when expanding the adoption of prophylactic measures.

Market Driver

The escalating volume of major surgical and orthopedic procedures serves as a primary market catalyst, requiring strict postsurgical prevention strategies to ensure patient safety. As healthcare systems clear pandemic-related backlogs, the frequency of high-risk interventions, such as total knee and hip arthroplasties, has risen, directly boosting the use of pharmacological prophylaxis and mechanical compression. This increase in surgical throughput necessitates that hospitals stock and administer prophylactic solutions to mitigate the deep vein thrombosis risks associated with operative trauma and prolonged immobilization. According to Stryker, January 2024, in the 'Fourth Quarter 2023 Operating Results', the company reported net sales growth of 11.5 percent to $5.8 billion, a performance largely attributed to the sustained momentum in surgical procedure volumes requiring concurrent preventative care.

Simultaneously, the rapid uptake of Novel Oral Anticoagulants (NOACs) is transforming the standard of care by providing superior safety profiles and easier administration compared to traditional vitamin K antagonists. Clinicians increasingly prefer these advanced therapies due to their predictable pharmacokinetics, which enhance patient compliance and reduce the need for continuous monitoring. According to Bristol Myers Squibb, February 2024, in the '2023 Annual Report', the leading oral anticoagulant Eliquis generated worldwide revenues of $12.2 billion, signaling a massive global shift toward these modern agents. This transition is further underscored by the persistent disease burden; according to the National Blood Clot Alliance, in 2024, blood clots affect approximately 900,000 people in the United States annually, driving the urgency for reliable prophylactic interventions throughout the continuum of care.

Market Challenge

A significant impediment facing the Global Venous Thromboembolism Prophylaxis Market is the risk of major bleeding associated with potent anticoagulant therapies. Clinicians frequently face the dilemma of balancing the benefits of clot prevention against the potential for life-threatening hemorrhagic complications, particularly among vulnerable groups like the elderly or patients recovering from extensive surgeries. This clinical caution often leads to the under-prescription of necessary pharmacological prophylaxis, dosage reductions, or premature therapy cessation. While clinically justified, such hesitation restricts the total volume of anticoagulants used and slows the adoption of prophylaxis protocols, thereby limiting overall market expansion.

This constraint is especially severe within high-risk patient populations that constitute a large segment of the addressable market. According to the American Society of Hematology, in 2023, medical inpatients and residents in long-term care facilities accounted for approximately 20% to 25% of all venous thromboembolism instances globally. Because these specific groups often present with comorbidities that increase their susceptibility to bleeding, the rigorous application of prophylaxis is frequently compromised by safety concerns, effectively curbing market penetration in a sector that otherwise generates substantial demand for preventative interventions.

Market Trends

The rise of portable and wearable mechanical prophylaxis devices is reshaping the recovery landscape by separating compression therapy from stationary hospital infrastructure. Unlike traditional pneumatic systems that keep patients tethered to bedside units, these battery-operated devices facilitate early mobilization, a critical factor in reducing venous stasis and enhancing patient adherence following discharge. This shift aligns with the increasing demand for home-based recovery solutions that preserve clinical efficacy without restricting patient mobility. The commercial viability of these technologies is highlighted by the financial results of key industry players; according to Enovis Corporation, February 2024, in the 'Fourth Quarter and Fiscal Year 2023 Results', the company's Prevention and Recovery segment posted full-year net sales growth of 5%, reflecting sustained demand for these mobile therapeutic solutions.

Simultaneously, the adoption of personalized prophylaxis protocols utilizing AI-driven risk assessment is superseding generic prevention strategies with precision medicine tools. Advanced algorithms now integrate with electronic health records to continuously monitor patient data, automatically identifying high-risk individuals who might be missed by manual scoring systems like Padua or Caprini. This automation ensures timely intervention for conditions such as pulmonary embolism and improves care coordination across fragmented hospital departments. The rapid uptake of these intelligent systems is evident in the growing reach of specialized AI providers; according to Viz.ai, January 2024, in the 'Viz.ai Adoption Surpasses 1,500 Hospitals Nationwide' press release, the user base for its AI-powered disease detection platform expanded by nearly 30% in 2023 to reach 45,000 healthcare providers.

Key Market Players

  • Arjo
  • Encompass Group
  • Argon Medical Devices
  • MEGO AFEK
  • Zenith Technical Innovations
  • Cook Medical
  • Bio Compression Systems
  • ThermoTek USA
  • Boston Scientific Corporation
  • Cardinal Health

Report Scope

In this report, the Global Venous Thromboembolism Prophylaxis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Venous Thromboembolism Prophylaxis Market, By Type

  • Lower Extremity
  • Upper Extremity

Venous Thromboembolism Prophylaxis Market, By End Use

  • Hospitals & Clinics
  • Ambulatory care Centers
  • Others

Venous Thromboembolism Prophylaxis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Venous Thromboembolism Prophylaxis Market.

Available Customizations:

Global Venous Thromboembolism Prophylaxis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Venous Thromboembolism Prophylaxis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Lower Extremity, Upper Extremity)
    • 5.2.2. By End Use (Hospitals & Clinics, Ambulatory care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Venous Thromboembolism Prophylaxis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Venous Thromboembolism Prophylaxis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Venous Thromboembolism Prophylaxis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Venous Thromboembolism Prophylaxis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End Use

7. Europe Venous Thromboembolism Prophylaxis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End Use

8. Asia Pacific Venous Thromboembolism Prophylaxis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Venous Thromboembolism Prophylaxis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Venous Thromboembolism Prophylaxis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Venous Thromboembolism Prophylaxis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Venous Thromboembolism Prophylaxis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End Use

10. South America Venous Thromboembolism Prophylaxis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Venous Thromboembolism Prophylaxis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Venous Thromboembolism Prophylaxis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Venous Thromboembolism Prophylaxis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Venous Thromboembolism Prophylaxis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Arjo
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Encompass Group
  • 15.3. Argon Medical Devices
  • 15.4. MEGO AFEK
  • 15.5. Zenith Technical Innovations
  • 15.6. Cook Medical
  • 15.7. Bio Compression Systems
  • 15.8. ThermoTek USA
  • 15.9. Boston Scientific Corporation
  • 15.10. Cardinal Health

16. Strategic Recommendations

17. About Us & Disclaimer